Orion Pharma (DHA:ORIONPHARM) Research & Development: BDT0 Mil (TTM As of Mar. 2026)


DHA:ORIONPHARM Orion Pharma Ltd DHA:ORIONPHARM
71 GF Score
Price BDT30.80
GF Value BDT20.19
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Orion Pharma Research & Development?

Orion Pharma DHA:ORIONPHARM +0.33% 71 Research & Development is BDT0 Mil as of Mar. 2026. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 71/100 and a GF Value™ of BDT20.19 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Orion Pharma's Research & Development for the three months ended in Mar. 2026 was BDT0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was BDT0 Mil.

Orion Pharma  (DHA:ORIONPHARM) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Orion Pharma Research & Development Related Terms

Orion Pharma Research & Development Historical Data

* Premium members only.

The historical data trend for Orion Pharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orion Pharma Research & Development Chart

Orion Pharma Annual Data
Trend Dec14 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.28 4.54 3.15 4.53 0.67

Orion Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
DHA:ORIONPHARM
71GF Score
Orion Pharma Ltd DHA:ORIONPHARM
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orion Pharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of BDT0 Mil mean?
Orion Pharma (DHA:ORIONPHARM) has a Research & Development of BDT0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Orion Pharma and its competitors.
Is Orion Pharma's Research & Development too high?
Orion Pharma's current Research & Development is BDT0 Mil. Overall, Orion Pharma has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Research & Development compare to CEG and VST?
Orion Pharma's Research & Development of BDT0 Mil can be compared against companies in the Utilities - Independent Power Producers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for an Utilities - Independent Power Producers company?
A good Research & Development depends on the Utilities - Independent Power Producers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Orion Pharma and its competitors. Orion Pharma's current Research & Development is BDT0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.19, compared to a current price of BDT30.80 — trading 52.6% above its estimated fair value. The current Research & Development is BDT0 Mil. Orion Pharma's overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Research & Development is BDT0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued. The current stock price of BDT30.80 is trading 52.6% above its estimated GF Value™ of BDT20.19. GuruFocus considers Orion Pharma to be Significantly Overvalued.

Key valuation signals for DHA:ORIONPHARM:

  • Research & Development: BDT0 Mil
  • GF Value™: BDT20.19 vs. price of BDT30.80 (52.6% above fair value)
  • GF Score™: 71/100 with 8 warning signs

No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orion Pharma Business Description

Address 153-154 Tejgaon Industrial Area, Orion House, Dhaka, BGD, 1208
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
71GF Score

Get the complete analysis for DHA:ORIONPHARM

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT30.80
Price
BDT20.19
GF Value